Kinnate Biopharma (NASDAQ:KNTE) Receives Maintains Rating from 500.com

500.com restated their maintains rating on shares of Kinnate Biopharma (NASDAQ:KNTE – Get Rating) in a report released on Thursday, Benzinga reports. A number of other brokerages have also commented on KNTE. Stifel Nicolaus dropped their price target on Kinnate Biopharma from $8.00 to $5.00 in a research note on Tuesday, April 18th. HC Wainwright […]

Related Keywords

United States ,Kinnate Biopharma ,Stifel Nicolaus ,Carll Gordon ,Securities Exchange Commission ,Blackrock Inc ,Jpmorgan Chase Co ,Metlife Investment Management ,Kinnate Biopharma Company Profile ,Kinnate Biopharma Inc ,Goldman Sachs Group ,Get Rating ,Moderate Buy ,Director Carl ,Exchange Commission ,Life Investment Management ,Biopharma Inc ,Cyclin Dependent Kinase ,Kinnate Biopharma Daily ,Nasdaq Knte ,Knte ,Medical ,Reiterated Rating ,500 Com Limited ,